Changes in glucagon-like peptide 1 and 2 levels in people with obesity after a diet-induced weight-loss intervention are related to a specific microbiota signature: A prospective cohort study.
Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors at 6 institutions in 2 countries.
M-Mar Rodríguez-PeñaEndocrinology and Nutrition Service, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain.ORCID 0000-0003-2553-9769
Brenno AstiarragaEndocrinology and Nutrition Service, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain.ORCID 0000-0003-2216-8974
Jesus SecoEndocrinology and Nutrition Service, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain.ORCID 0000-0002-4049-8873
Victoria Ceperuelo-MallafréEndocrinology and Nutrition Service, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain.ORCID 0000-0002-4460-9761
Adrià CaballéInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Vicente Pérez-BrocalDepartment of Genomics and Health, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain.
Camille Stephan-Otto AttoliniInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Andrés MoyaDepartment of Genomics and Health, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain.
Gemma LlauradóCIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain.
Ana MegíaEndocrinology and Nutrition Service, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain.ORCID 0000-0002-5101-9452
Silvia PelliteroEndocrinology and Nutrition Department, Institute Research and Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain.
Núria VilarrasaCIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain.
Sonia Fernández-VeledoEndocrinology and Nutrition Service, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain.ORCID 0000-0003-2906-3788
Joan VendrellEndocrinology and Nutrition Service, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain.ORCID 0000-0002-6994-6115
Instituto de Salud Carlos III · ESInstitut de Recerca Biomèdica Catalunya Sud · ESInstitute for Research in Biomedicine · ESUniversitat Autònoma de Barcelona · ESConsejo Superior de Investigaciones Científicas · ESFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ES
Funding
Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas CB07708/0012Generalitat Valenciana PROMETEO/2018/133Instituto de Salud Carlos III PI14/00228Instituto de Salud Carlos III PI17/0153Instituto de Salud Carlos III PI20/00338Ministerio de Ciencia e Innovación PID2019-105969GB-I00Ministerio de Ciencia e Innovación RTI2018-093919-B-I00Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders CB07708/0012Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders CP10/00438Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders CPII16/00008Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders Instituto de Salud Carlos III. S.F-V.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Changes in glucagon-like peptide 1 and 2 levels in people with obesity after a diet-induced weight-loss intervention are related to a specific microbiota signature: A prospective cohort study. · full record | OpenQuestion